HALIFAX,
Jan. 29, 2013 /CNW/ - MedMira Inc.,
(MedMira) (TSXV: MIR), a developer of rapid diagnostic technology
and solutions, today announced that the Company's Board of
Directors was elected at MedMira's 2013 Annual General and Special
Meeting of Shareholders, which was held on January 25th, 2013. Mr.
Hermes Chan, Dr. Shou-Ching Tang, Mr. Romano Robusto and Mr. Markus Meile were re-elected as Directors of the
Company. Dr. Michael Sidler, a
representative of the Company's majority shareholder, OnSite Lab
Holding AG, was also elected.
"We are very pleased to welcome Dr. Sidler to
our Board of Directors," said Hermes
Chan, CEO and Director, MedMira. "His expertise in
investment and technology commercialization in early-stage
companies will make a significant contribution to our Board's role
in strategic oversight and business execution as we position
ourselves for growth in 2013."
Shareholders approved all other matters considered at the
meeting including the appointment of Deloitte as the Company's
auditors and ratification of the stock option plan.
About MedMira
MedMira is a leading developer and manufacturer
of flow-through rapid diagnostics and technologies. MedMira is the
only Canadian company to be awarded US Army contracts for the
development of rapid tests for HIV and Hepatitis viruses. The
Company's testing solutions provide hospitals, labs, clinics and
individuals with reliable, rapid diagnosis for diseases such as HIV
and hepatitis C in just three minutes. The Company's tests are sold
under the Reveal®, Multiplo™ and Miriad brands in global markets.
MedMira is located in Halifax, Nova
Scotia, Canada. www.medmira.com.
This news release contains forward-looking
statements, including statements relating to growth in the
Company's business, earnings and profitability, and trends in
demand for the Company's products, which involve risk and
uncertainties and reflect the Company's current expectation
regarding future events including statements regarding possible
future growth and new business opportunities. Actual events
could materially differ from those projected herein and depend on a
number of factors including, but not limited to, changing market
conditions, successful and timely completion of clinical studies,
uncertainties related to the regulatory approval process,
establishment of corporate alliances and other risks detailed from
time to time in the company quarterly filings.
Neither TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
SOURCE MEDMIRA INC.
